Mid Term
May 6, 2024 | Daily JAM, Mid Term, Morning Briefing |
Social Security and Medicare will run out of money in just over a decade, a new government report warned Monday, May 6. Where’s the good news? Insolvency will come late than forecast last year thanks to the hot job market. The trustees for the massive retirement programs project that Social Security will be insolvent by 2035, and Medicare by 2036, which would force benefit cuts. Congress and the White House could act in 2025 as part of an intense debate on the extension of the Trump tax cuts of 2017, which are due to expire in 2027.
April 26, 2024 | Daily JAM, Mid Term, Morning Briefing |
Yesterday we had a report of core Personal Consumption Expenditure for March that showed core inflation ticking up to an annual rate of 3.8% from 3.7%. Core inflation, if you remember, looks at prices after excluding more volatile food and energy prices, The reasonable conclusion was that inflation was remaining stubbornly higher than the Federal Reserves % target. And that the first cut to interior rates from the Fed wouldn’t come until December, instead of July or September. Today we got the report on all-items PCE inflation.
April 25, 2024 | Daily JAM, Mid Term, Morning Briefing |
How views on interest rates have changed since the start of 2024. Then, in January, the consensus view called for as many as six interest rate cuts from the Federal Reserve in 2024 for a total of 150 basis points in cuts to the Fed’s benchmark interest rate. Today, after a dip in first quarter GDP below a 2% annual rate and an uptick in core PCE inflation, the markets are pricing in just 33 basis points in rate cuts and quite possibly no cut until the Fed’s December 18 meeting.
April 25, 2024 | Daily JAM, GOOG, Long Term, Mid Term, Stock Alerts, Top 50 Stocks |
After the close today, Alphabet (GOOG) reported revenue of $80.5 billion, easily beating the consensus projection of $78.7 billion. Earning per share came in at $1.89 versus expectations for $1.50 a share. And none of the worries before the news turned out to be problems. Advertising revenue rose 13% to $61.7 billion. Ad revenue for YouTube–an area of worry rose 21% to $8.09 billion. Subscriptions, platforms and devices revenue jumped 18%.
April 21, 2024 | Daily JAM, Mid Term |
It’s been a tough month for Treasuries with yields rising on a re-thinking of when the Federal Reserve might begin to cut interest rates. The yield on the 10-year Treasury closed at 4.62% on Friday. That’s an increase in yield of 35 basis points in a month. (When yields climb, bond prices fall.) And this week the Treasury will auction a combined $183 billion of two-, five- and seven-year Treasury notes. Ans that’s ahead of the latest update on the Personal Consumption Expenditures index, the Federal Reserve’s preferred inflation measure.
April 16, 2024 | Daily JAM, Mid Term, Morning Briefing |
China reported faster-than-expected economic growth in the first quarter–but… Although Gross Domestic Product climbed 5.3% in the quarter–a faster rate of growth than in the first quarter of 2023 and above economist estimates, most of the good news came from the first two months of the quarter. In March growth in retail sales slumped and industrial output fell short of forecasts. That doesn’t bode well for the rest of 2024.
April 15, 2024 | Daily JAM, Mid Term |
Can’t figure Tesla (TSLA) out? Welcome to the club. The stock was down another 5.59% today, April 15, and is now down 31% for 2024. Maybe investors will get some clarity on the company’s identity and strategy when it announced earnings on April 23. Wall Street analysts expect earnings of 36 cents a share against earnings of 73 cents a share in 2023. I think that strategic clarity is actually more important than quarterly earnings at this point for Tesla.
April 12, 2024 | Daily JAM, Mid Term |
All good things come to an end. After seven straight quarters of record levels of profits from net interest income, the spread between what earns by lending and what it pays depositors to raise funds, JPMorgan Chase (JPM) reported that net interest income slightly missed analyst estimates for the first quarter. The quarter the company reported today certainly wasn’t a disaster. The bank earned $23.1 billion in net interest income in the period, up 11% from the first quarter of 2023. But the end of the beat and raise guidance of the last year and a half plus an increase in costs were enough to lead to substantial selling today, April 12. The shares finished the day down 6.47% at $182.79. Analysts and investors were clearly hoping for more.
April 11, 2024 | Daily JAM, Mid Term, Morning Briefing |
So why was this so important today? Important enough to send the yield on the 10-year Treasury up another 3 basis points to 4.58%.The Producer Price Index for final demand rose 0.2 percent in March, seasonally adjusted, the Bureau of Labor Statistics reported today. Final demand prices moved up 0.6% in February and 0.4% in January. On an unadjusted basis, the index for final demand increased 2.1% for the 12 months ended in March, the largest advance since rising 2.3% for the 12 months ended April 2023..The March increase in the index for final demand is attributable to a 0.3% rise in prices for final demand services. In contrast, the index for final demand goods edged down 0.1%. Look at the last set of numbers.
March 26, 2024 | Daily JAM, Jubak Picks, LLY, Mid Term, Morning Briefing, NVO, Stock Alerts, VKTX |
First, it was Viking Therapeutics (VKTX) on the attack with trial results that shows its GLP-1 dibetes/weight loss drug out performing current leader of the pack drugs fro Novo Nordisk (NVO) and Eli Lilly (LLY). On the news Viking soared.
Then Novo Nordisk struct back with data of its own showing progress on an oral formulation of its rugs. (All existing GLP-1 drugs are delivered by injection.) That cratered Viking Shares. Now, March 26, Viking has released new Phase 1 trial data from a multiple ascending dose study of the oral version of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
March 22, 2024 | Daily JAM, Mid Term, Videos |
Today’s video is What Powell Said, and What the Market Heard. Jerome Powell, Chair of the Federal Reserve, tried to walk a fine line during Wednesday’s press conference. He said that while inflation is sticky; he’s still confident in a soft landing at 2.0% and that they will cut rates once they confirm that a 2.0% rate is achievable. What the market heard was “we can tolerate higher inflation for longer while still cutting rates, ” and this is backed up by the Fed’s Dot Plot economic projections . The Dot Plot lays out 2-3 cuts in 2024 even though core PCE inflation rates are expected to be at 2.6% at the end of the year–not the target of 2.0%. That 2.0% target will now not likely be reached until the end of 2026, the Fed’s own economic projections say. The market reacted to the news that they heard as “the Fed is no longer insisting on the 2.0% target and will be cutting rates this year,” by hitting its 20th all-time high for 2024. The market heard happy days are here again, and rallied.
March 20, 2024 | Daily JAM, Jubak Picks, Mid Term, Stock Alerts |
Today’s Hot Button Moves NOW video is Buy Madrigal Pharmaceuticals (MDGL). This biotech company just received U.S. Food and Drug Administration approval for the first drug available for treating MASH (formerly known as NASH). MASH is a liver disease where fat builds up and compromise liver function. It’s measured in stages (1-4) and at stage 4, you need a liver transplant. Companies have long worked toward a treatment for the disease but have failed in trials or in getting FDA approval. The major achievements for Madrigal are efficacy in stopping the disease from progressing to the next stage and a clean label and no “black box warnings.” Additionally, this drug does not require a liver biopsy before a doctor can prescribe it and will be available after a much less invasive test. The market for this drug is forecast at $5 billion a year market. Madrigal will be able to start selling this drug in April. The Medical Technology Stock Letter, my preferred source on all things biotech, suggests buying MDGL below $300 with a target price of $400. I’m adding Madrigal Pharmaceuticals to my 12-18 month Jubak’s Picks Portfolio.
